May 14, 2021 -- Interline Therapeutics has raised $92 million to be used to expand its research platform and advance six preclinical therapeutic programs.
Foresite Capital and ARCH Venture Partners co-led the financing, which will be used to support platform development and therapeutic programs focused on inflammatory disease and cancer. Interline will use a combination of genomics, proteomics, structural biology, and computational chemistry to systematically map and modulate proteins to develop a precision medicine platform capable of correcting dysfunctional disease networks.
The company will continue to collaborate with Foresite Labs in the fields of data science and genomics. Interline also launched with foundational collaborations with University of California, San Francisco and Memorial Sloan Kettering Cancer Center, as well as an internationally recognized team of founding scientific advisors.
Copyright © 2021 scienceboard.net